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Medication-overuse headache (MOH) [1] is one of the
headache forms that most frequently prompts patients to
consult a specialist headache centre. Literature data indi-
cate an approximately 1%–2% prevalence of MOH in the
general population [2–4]. Around 40% of patients seen at
headache centres present with a chronic form of headache
and 80% of these chronic headache patients make exces-
sive use of symptomatic drugs [4]. A 2003 study by
Dowson on the profile of patients seen at UK headache
centres revealed that 60% suffer from a chronic form of
headache and that 66% of these chronic headache suffer-
ers regularly use analgesics [5].
The literature contains few long-term observational
studies investigating the risk of relapse into overuse.
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headache (MOH) is one of the
headache forms that most frequent-
ly prompts patients to consult a
specialist headache centre. The
prevalence of this form in the gen-
eral population is approximately
1%–2%. Around 40% of patients
seen at headache centres present
with a chronic form of headache
and 80% of this chronic headache
patients make excessive use of
symptomatic drugs. MOH shows a
clinical improvement, accompained
by a reduction in the consumption
of analgesic drugs, if patients are
submitted to detoxification therapy.
But detoxification is only the first
stage in a long and complex course
of care and global approach
demands adequate follow-up visit
to prevent early relapses. At the
Headache Centre of the C. Mondino
Institute of Neurology in Pavia, a
course of care (CARE) has been
developed for the complente man-
agement of patients with MOH both
during Hospitalization and durimg
the subsequent follow-up period.
CARE IS designed to trace the clini-
cal, psychopathological and phar-
macological profile of MOH in the
short-, medium- and long-term; to
look for factors possibility predic-
tive of relapse; to assess the direct
costs linked to overuse-headache in
the year leading up to and follow-
ing detoxification; and to evaluate
disability, in terms of working days
lost, before and after detoxification.
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Schnider et al. [6], reporting the longest follow-up to date
(5 years), found that 39.5% of patients relapsed into drug
overuse, and also that frequency and intensity of headache
changed substantially within the first two years of drug
withdrawal. In a prospective study, conducted after the
introduction of the triptans into clinical practice, Katsarava
et al. [7] showed that relapse into overuse occurred within
6 months of detoxification in 31% of patients, and within a
year in 36%; the same author, in a subsequent study,
reported a relapse rate of 45% at 4 years [8].
Overall, the literature data seem to indicate that there
is a high risk of relapse in the first year following detoxi-
fication.
MOH shows a clinical improvement, accompanied by
a reduction in the consumption of analgesic drugs, if
patients are submitted to detoxification therapy. But
detoxification is only the first stage in a long and complex
course of care and a global approach demands adequate
follow-up visits to prevent early relapses.
At the Headache Centre of the C. Mondino Institute of
Neurology in Pavia, a course of care (CARE) has been
developed for the complete management of patients with
MOH both during hospitalisation and during the subse-
quent follow-up period. CARE is designed to trace the clin-
ical, psychopathological and pharmacological profile of
MOH patients; to evaluate the therapeutic efficacy of
detoxification; to establish the percentage of patients pre-
senting with relapses of MOH in the short-, medium- and
long-term; to look for factors possibly predictive of
relapse; to assess the direct costs linked to overuse
headache in the year leading up to and following detoxifi-
cation; and to evaluate disability, in terms of working days
lost, before and after detoxification.
All patients with a possible diagnosis of MOH admit-
ted for the first time to the Headache Unit at the C.
Mondino Institute of Neurology are being recruited for
this study. All those enrolled are admitted as inpatients for
an initial period of 8–10 days, during which they undergo
infusion-detoxification therapy. Using an ad hoc data
sheet, a comprehensive personal and family history of the
patient is taken, as well as details of his or her headache
and drug use. Each patient is administered specific ques-
tionnaires investigating quality of life and disability.
Patients are also asked to supply information relating to
working days lost or on which they worked at suboptimal
efficiency due to their headache, and to expenses incurred
in the past as a result of their headache (tests, examina-
tions, hospital stays, drugs).
Upon entry to the study, each patient undergoes a stan-
dard battery of tests to evaluate the presence of drug
abuse/dependence disorders (semi-structured interview,
DSM-IV), the presence of comorbid psychopathologies
and personality profile (MMPI-2).
The patient is then submitted to infusion-detoxifica-
tion therapy daily throughout the period of hospitalisation
(8–10 days depending on the case). Any abstinence symp-
toms, pain and neurovegetative symptoms such as nausea
and vomiting are appropriately controlled. Preventive
therapy is initiated during the hospital stay.
The course of care also includes rehabilitative coun-
selling and the imparting of instructions for the post-dis-
charge period. On discharge, each patient is given: (1) a
treatment regimen to be followed at home; (2) a letter
informing the patient’s GP of his or her participation in
the programme; (3) the dates of recall scheduled during
the planned observation period; (4) a diary for recording
days with headache, use of symptomatic drugs and days of
menstruation.
The diagnosis of MOH is confirmed 2 months after
discharge. On all follow-up visits the course of the
headache is checked, considering number of days with
headache and use of symptomatic drugs, and, if necessary,
the treatment regimen is reviewed.
To prevent patients from altering, independently, their
treatment regimen (and thus their clinical course), they are
also contacted by telephone in between visits.
At the present time, 113 patients (91 women and 22
men, mean age 44.8±11.1 years) have been recruited.
Their drug overuse can be subdivided as follows: 24.8%
triptans, 24.8% analgesics, 2.6% opioids, 31.9% combina-
tion analgesics, 2.6% combinations of acute medications
and 13.3% more than one overuse.
Our preliminary findings indicate good compliance on
the part of the patients, who appreciate, above all, the fact
that they are always seen by the same doctor, the schedul-
ing of the visits and the intermediate contacts by tele-
phone. Only 4 patients have been lost to follow up.
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